Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. It is designed to operate with precision and perform specific movements creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs.
Currently at the approval stage, R-One™ commercialization and clinical use will start in Europe in early 2019.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.